Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement C1s is a serine protease and a key component of the classical pathway of the complement system. It forms part of the C1 complex together with C1q and C1r. Upon activation by C1q binding to antibody-antigen complexes, C1s cleaves complement components C4 and C2, initiating the complement cascade. C1s also cleaves non-canonical substrates involved in tissue renewal and immunogenicity modulation. Its activity is regulated by C1 inhibitor (C1Inh), and deficiency can lead to hereditary angioedema. C1s serves as a diagnostic marker and therapeutic target for autoimmune and inflammatory conditions.
Serine protease inhibitor
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement Component C1s (C1s).